Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma and prior anti-tumor therapy: A subanalysis from the sharp trial

被引：9

作者：

Galle, P. ^{[1
]}

Blanc, J. ^{[2
]}

Van Laethem, J-L. ^{[3
]}

Marrero, J. ^{[4
]}

Beaugrand, M. ^{[5
]}

Moscovici, M. ^{[6
]}

Shan, M. ^{[7
]}

Nadel, A. ^{[7
]}

Voliotis, D. ^{[8
]}

Bruix, J. ^{[9
]}

Llovet, J. M. ^{[9
,10
]}

机构：

[1] Univ Mainz Klinikum, Mainz, Germany

[2] CHU, Hop St Andre, Bordeaux, France

[3] Erasme Univ Hosp, B-1070 Brussels, Belgium

[4] Univ Michigan, Ann Arbor, MI 48109 USA

[5] Hop Jean Verdier, Bondy, France

[6] Bayer Schering Pharma, Milan, Italy

[7] Bayer Healthcare Pharmaceut, West Haven, CT USA

[8] Bayer Schering Pharma, Global Clin Dev, Wuppertal, Germany

[9] Hosp Clin Barcelona, Liver Unit, CIBERehd, IDIBAPS,BCLC Grp, Barcelona, Spain

[10] Mt Sinai Sch Med, Div Liver Dis, New York, NY USA

来源：

JOURNAL OF HEPATOLOGY | 2008年 / 48卷

关键词：

D O I：

10.1016/S0168-8278(08)60996-4

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

994

引用

页码：S372 / S372

页数：1

共 50 条

[21] Hexokinase-II Inhibition Synergistically Augments the Anti-tumor Efficacy of Sorafenib in Hepatocellular Carcinoma
Yoo, Jeong-Ju
Yu, Su Jong
Na, Juri
Kim, Kyungmin
Cho, Young Youn
Lee, Yun Bin
Cho, Eun Ju
Lee, Jeong-Hoon
Kim, Yoon Jun
Youn, Hyewon
Yoon, Jung-Hwan
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (06)
[22] Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma
Masayoshi Yada
Akihide Masumoto
Kenta Motomura
Hirotaka Tajiri
Yusuke Morita
Hideo Suzuki
Takeshi Senju
Toshimasa Koyanagi
World Journal of Gastroenterology, 2014, (35) : 12581 - 12587
[23] Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma
Yada, Masayoshi
Masumoto, Akihide
Motomura, Kenta
Tajiri, Hirotaka
Morita, Yusuke
Suzuki, Hideo
Senju, Takeshi
Koyanagi, Toshimasa
WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (35) : 12581 - 12587
[24] Sorafenib for the Treatment of Alcohol-Related Hepatocellular Carcinoma (HCC): Subanalysis of the Phase III SHARP Trial
Trojan, J.
Craxi, A.
Porta, C.
Sangiovanni, A.
Shan, M.
Nadel, A.
Voliotis, D.
Bruix, J.
Llovet, J.
ONKOLOGIE, 2010, 33 : 84 - 84
[25] Sorafenib in the treatment of advanced Hepatocellular Carcinoma (HCC) -: Experiences beyond the sharp trial
Woerns, M.-A.
Schulze-Bergkamen, W.
Schuchmann, M.
Otto, G.
Galle, P. R.
Weinmann, A.
ONKOLOGIE, 2008, 31 : 80 - 80
[26] SAFETY OF SORAFENIB THERAPY IN ELDERLY ADULTS WITH ADVANCED HEPATOCELLULAR CARCINOMA
Francini, Edoardo
Mazzaroppi, Silvia
Fiaschi, Anna I.
Petrioli, Roberto
Laera, Letizia
Roviello, Giandomenico
Pira, Teresa
Pellicelli, Adriano M.
Bianco, Vincenzo
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2014, 62 (11) : 2204 - 2205
[27] Efficacy and Safety of the Combination of Pravastatin and Sorafenib for the Treatment of Advanced Hepatocellular Carcinoma (ESTAHEP Clinical Trial)
Riano, Ioana
Martin, Leticia
Varela, Maria
Serrano, Trinidad
Nunez, Oscar
Minguez, Beatriz
Rodrigues, Pedro M.
Perugorria, Maria J.
Banales, Jesus M.
Arenas, Juan I.
CANCERS, 2020, 12 (07) : 1 - 14
[28] Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma
Da Fonseca, Leonardo Gomes
Barroso-Sousa, Romualdo
Alves Bento, Afonso Da Silva
Blanco, Bruna Paccola
Valente, Gabriel Luis
Flesch Pfiffer, Tulio Eduardo
Hoff, Paulo Marcelo
Sabbaga, Jorge
MOLECULAR AND CLINICAL ONCOLOGY, 2015, 3 (04) : 793 - 796
[29] EFFICACY AND SAFETY OF SORAFENIB IN PATIENTS IN THE ASIA-PACIFIC REGION WITH ADVANCED HEPATOCELLULAR CARCINOMA
Cheng, Ann-Lii
ANNALS OF ONCOLOGY, 2010, 21 : 5 - 5
[30] Efficacy and safety of sorafenib in patients aged 80 years and older with advanced hepatocellular carcinoma
Yasui, Kohichiroh
Jo, Masayasu
Nishimura, Takeshi
Yamaguchi, Kanji
Sumida, Yoshio
Mitsuyoshi, Hironori
Minami, Masahito
Itoh, Yoshito
HEPATOLOGY, 2013, 58 : 1256A - 1257A

← 1 2 3 4 5 →